Mucommune is a professional R&D organization

with a strong track record in advancing early-stage academic discoveries and inventions into IND-enabling preclinical studies and clinical development.

 

Technologies Mucommune has helped launch or are currently advancing include best-in-class mAb therapies for various acute respiratory infections (Inhalon), first-in-class interventions for female reproductive health (Elleon), and molecularly-specific interventions against polyethylene glycol immunogenicity and pre-existing immunity (Polyon).